Provexis plc (PXS) - Total Liabilities
Based on the latest financial reports, Provexis plc (PXS) has total liabilities worth GBX230.95K GBX (≈ $28.10 USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Provexis plc - Total Liabilities Trend (2004–2025)
This chart illustrates how Provexis plc's total liabilities have evolved over time, based on quarterly financial data. See PXS net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Provexis plc Competitors by Total Liabilities
The table below lists competitors of Provexis plc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Lion Group Holding Ltd
NASDAQ:LGHL
|
USA | $42.46 Million |
|
Guess? Inc.
NYSE:GES
|
USA | $2.44 Billion |
|
Rajvir Industries Limited
NSE:RAJVIR
|
India | Rs1.13 Billion |
|
Windar Photonics Plc
LSE:WPHO
|
UK | GBX2.79 Million |
|
GETT Gold Inc
V:GETT
|
Canada | CA$18.53 Million |
|
Eden Research plc
LSE:EDEN
|
UK | GBX2.85 Million |
|
SkinBioTherapeutics PLC
LSE:SBTX
|
UK | GBX2.71 Million |
|
International Zeolite Corp
V:IZ
|
Canada | CA$2.88 Million |
Liability Composition Analysis (2004–2025)
This chart breaks down Provexis plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Provexis plc stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.65 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.27 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Provexis plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Provexis plc (2004–2025)
The table below shows the annual total liabilities of Provexis plc from 2004 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | GBX248.21K ≈ $30.20 |
-19.27% |
| 2024-03-31 | GBX307.45K ≈ $37.41 |
+63.24% |
| 2023-03-31 | GBX188.34K ≈ $22.92 |
+19.27% |
| 2022-03-31 | GBX157.91K ≈ $19.21 |
+4.80% |
| 2021-03-31 | GBX150.68K ≈ $18.33 |
+0.40% |
| 2020-03-31 | GBX150.08K ≈ $18.26 |
+21.87% |
| 2019-03-31 | GBX123.14K ≈ $14.98 |
+37.77% |
| 2018-03-31 | GBX89.38K ≈ $10.88 |
-32.95% |
| 2017-03-31 | GBX133.31K ≈ $16.22 |
+17.20% |
| 2016-03-31 | GBX113.75K ≈ $13.84 |
-0.29% |
| 2015-03-31 | GBX114.08K ≈ $13.88 |
+5.42% |
| 2014-03-31 | GBX108.21K ≈ $13.17 |
-95.61% |
| 2013-03-31 | GBX2.47 Million ≈ $299.92 |
+16.49% |
| 2012-03-31 | GBX2.12 Million ≈ $257.46 |
+275.18% |
| 2011-03-31 | GBX564.00K ≈ $68.62 |
+91.19% |
| 2010-03-31 | GBX295.00K ≈ $35.89 |
+26.07% |
| 2009-03-31 | GBX234.00K ≈ $28.47 |
-35.18% |
| 2008-03-31 | GBX361.00K ≈ $43.92 |
-56.97% |
| 2007-03-31 | GBX839.00K ≈ $102.08 |
+3.97% |
| 2006-03-31 | GBX807.00K ≈ $98.19 |
-14.42% |
| 2005-03-31 | GBX943.00K ≈ $114.74 |
+338.60% |
| 2004-03-31 | GBX215.00K ≈ $26.16 |
-- |
About Provexis plc
Provexis plc, together with its subsidiaries, develops, licenses, and sells functional foods, medical foods, and dietary supplements worldwide. The company offers syrup and powder versions of Fruitflow, a tomato extract that reduces the propensity for aberrant blood clotting typically associated with cardiovascular diseases, such as heart attack and stroke used in various foods, beverages, and di… Read more